Cardiology AdvisorOnce-Daily Oral Wegovy Now Available for Weight Loss

Novo Nordisk launched the first oral GLP-1 receptor agonist for weight loss, with once-daily semaglutide tablets now available at retail pharmacies and major telehealth platforms. The OASIS 4 trial showed 13.6% body weight reduction versus 2.4% with placebo in 307 adults with obesity or overweight without diabetes.

Clinical Considerations

• Oral semaglutide requires a strict 30-minute fasting window after ingestion, taken with water only, limiting flexibility compared to the weekly injection
• Switching protocol from injectable Wegovy 2.4mg: initiate the 25mg tablet 1 week after the final injection dose
• Four-dose escalation over 91 days mirrors injectable titration logic; skipping escalation increases GI adverse event risk
• Nausea, vomiting, and diarrhea remain the most common adverse reactions, consistent with the injectable formulation

Practice Applications

• Counsel patients that the 30-minute pre-meal fasting window is non-negotiable for adequate absorption; document adherence barriers upfront
• Identify injection-averse or needle-phobic patients on your panel as candidates for the oral formulation
• Anticipate telehealth-driven patient self-initiation through Ro, LifeMD, or GoodRx; reconcile prescriptions at every visit
• Confirm cardiovascular risk reduction indication applies to adults with established CV disease plus obesity or overweight, not all patients

More Device & Drug Approvals